Conduit Pharmaceuticals (CDT) announces that its board of directors has approved a 1-for-100 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Annual Meeting of Stockholders held on December 18, 2024. They granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals partners with Agility Life Sciences
- Conduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock Split
- Conduit Pharmaceuticals Leverages AI for Drug Development
- Conduit Pharmaceuticals to enter agreement with SARBOR
- Conduit Pharmaceuticals files to sell 75M shares of common stock for holders